

*In re: Roberts et al.*  
*USSN: 09/826,609*  
*Filed: April 5, 2001*  
*Page 2*

- 12
- (b) determining the protein corresponding to said identified polynucleotide;
  - (c) determining if said protein is immunogenic comprising the steps of:
    - (i) introducing a gene transfer vector containing a second polynucleotide comprising a sequence corresponding to said protein into a antigen presenting cell (APC) under conditions whereby said polynucleotide is expressed by said antigen presenting cell;
    - (ii) culturing naïve immune effector cells with said antigen presenting cell under conditions whereby said naïve immune effector cells are educated to recognize antigens presented on the surface of said antigen presenting cell in the context of an MHC molecule;
    - (iii) determining if said educated immune effector cells can lyse said target cancer cell,

wherein the ability of said protein to elicit an immune response against said target cancer cell is indicative of a putative cancer therapeutic.

26. (New) The method of claim 25 wherein said antigen presenting cell is a dendritic cell.

---

#### **REMARKS**

Applicants respectfully request entry of the newly presented claims, Claims 25-26, into the instant application.

No new matter is added by these amendments. Support for the feature of testing the protein of interest via transfection of an antigen presenting cell is found throughout